Gross margin surged from 24.1% to 59.3% due to direct commercialization.
Completed an $86 million net equity offering in May 2026.
Net loss widened to $32.3 million as SG&A expenses exploded.
Amended loan agreement increased facility to $140 million with strict covenants.
The Q1 2026 filing reveals a company in the midst of a high-stakes structural transformation. By reclaiming its commercial rights from Ascensia, Senseonics has successfully proven that it can drive significant top-line growth and achieve superior gross margins. However, the transition has shifted the financial burden from the partner to the company's own balance sheet, manifesting as a sharp spike in SG&A expenses and a widening quarterly net loss. Investors are now weighing a classic trade-off between operational control and financial stability. While the 'fortress' balance sheet created by recent financing provides a temporary shield, the long-term viability of the business depends on whether the direct sales model can reach a break-even point before the current cash reserves are exhausted. The successful closing of European asset purchases and the progress of the Gemini pivotal study will be the primary indicators of whether this pivot leads to sustainable profitability or continued capital dependency.